Search company, investor...

Founded Year




Total Raised


Market Cap


Stock Price




About Xencor

Xencor is a company focused on the development of antibody and cytokine therapeutics, operating within the biotechnology and pharmaceutical industry. The company's main offerings include the design and development of proteins and biotherapeutics, specifically antibodies, that are used to treat various conditions such as autoimmune diseases, asthma, and cancer. These antibodies are engineered to enhance natural immune functions while maintaining a high degree of similarity to natural antibodies, resulting in potent, safe, and long-lasting treatments. It was founded in 1997 and is based in Monrovia, California.

Headquarters Location

111 West Lemon Ave

Monrovia, California, 91016,

United States




Expert Collections containing Xencor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xencor is included in 1 Expert Collection, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Xencor Patents

Xencor has filed 282 patents.

The 3 most popular patent topics include:

  • immune system
  • immunology
  • clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors



Latest Xencor News

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration

Feb 22, 2024

Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing and received ARTA treatment were identified in the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. Patients were stratified according to the timing of genomic testing relative to the first ARTA treatment (pre-/post-ARTA). Clinical outcomes such as time to progression, PSA response, and overall survival were compared based on alteration types. Results In total, 540 CRPC patients who received ARTA and had tissue-based (n = 321) and/or blood-based (n = 244) genomic sequencing were identified. Median age was 62 years (range 39−90) at the time of the diagnosis. Majority were White (72.2%) and had metastatic disease (92.6%) at the time of the first ARTA treatment. Pre-ARTA genomic testing was available in 24.8% of the patients, and AR mutations and amplifications were observed in 8.2% and 13.1% of the patients, respectively. Further, time to progression was longer in patients with AR amplifications (25.7 months) compared to those without an AR alteration (9.6 months; p = 0.03). In the post-ARTA group (n = 406), AR mutations and AR amplifications were observed in 18.5% and 35.7% of the patients, respectively. The most common mutation in post-ARTA group was L702H (9.9%). Conclusion In this real-world clinicogenomics database-driven study we explored the development of AR alterations and their association with ARTA treatment outcomes. Our study showed that AR amplifications are associated with longer time to progression on first ARTA treatment. Further prospective studies are needed to optimize therapeutic strategies for patients with AR alterations. Introduction Prostate cancer is the most commonly diagnosed non-cutaneous cancer among men in the United States, with an estimated incidence of 268,000 cases annually [ 1 ]. Suppression of the androgen signaling pathway has been the mainstay of treatment of prostate cancer since the landmark discovery by Huggins and Hodges of the androgen dependence of prostate cancer in 1941 [ 2 ]. In the setting of advanced or metastatic disease, treatment is focused on reducing androgen levels with surgical orchiectomy or medical castration and blocking androgen receptor activation [ 3 , 4 ]. While multiple treatment agents have been developed, outcomes differ widely, and validated biomarkers for treatment response or resistance are needed to help guide treatment selection. The growing ease and affordability of genomic profiling have enabled more prostate cancer patients to undergo blood-based and/or tissue-based genomic sequencing. Approval of agents such as olaparib, the first biomarker selected therapy for prostate cancer, has catapulted us into the modern era of broad-scale sequencing for all men with advanced disease [ 5 ]. These approaches have, in turn, provided a foundation for a body of literature seeking to identify actionable alterations and predictive genomic signatures [ 6 , 7 ]. The most commonly altered genes in primary prostate cancer are ETS fusions, PTEN, SPOP, TP53, and FOXA1 [ 8 ]. Furthermore, in the metastatic castration resistant disease setting, alterations in AR, TP53, MYC, ZMYM3, APC, and RB1 are reported to be significantly enriched compared to primary prostate cancer [ 9 ]. Although the predictive role of many of these genomic alterations is still being explored, there is heterogeneity in interpretating the clinical significance of AR gene alterations in patients with advanced disease. The AR gene encodes a nuclear receptor that is activated following the binding of androgenic hormones and regulates the transcription of several growth and differentiation-related genes required for the survival of prostatic cells [ 10 ]. Indeed, the majority of prostate cancers are driven by the alterations in AR-signaling [ 4 , 11 ]. Affected AR gene domain types, including mutations in the ligand binding domain, gene body and/or enhancer amplifications, or intronic structural rearrangements resulting in alternative splicing, can yield distinct biological characteristics and could potentially underlie the differential treatment response observed with AR targeted agents (ARTA). AR gene amplifications primarily occur in response to androgen deprivation therapy and are observed in more than 50% of patients with castration-resistant prostate cancer [ 12 , 13 , 14 ]. AR amplifications have been associated with resistance to enzalutamide and abiraterone acetate treatment [ 15 , 16 , 17 , 18 ]. Among non-metastatic prostate cancer patients, AR gene anomalies, while less common, have been associated with poorer clinical outcomes [ 19 ]. Several AR mutations have been implicated in therapeutic resistance to ARTA, often through AR activation by glucocorticoids and other sex hormones (e.g. L702H, H875Y) or gain of function mutations that confer AR agonist activity to AR antagonists (e.g., T878A, H875, F877L, W742C) [ 12 , 17 ], Discrepancies in the current literature, as well as the conflicting results from various genomic analyses, further complicates effective, evidence-based treatment selection among patients with prostate cancer. Given the existing knowledge gaps in the clinical relevance of AR alterations in relation to ARTA use, we embarked on our current study. In this study by utilizing a multi-institutional clinical and genomic database, we examined the association between clinical outcomes and AR alteration types, as well as the time of occurrence of alterations relative to the systemic treatment. Methods Study design and patient selection A retrospective analysis was conducted using the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database, which includes deidentified clinical and genomic data from patients with advanced prostate cancer (metastatic hormone sensitive or castration resistant) treated at 18 academic centers [ 20 ]. Patients had germline and somatic genomic testing (tissue, blood and/or germline) through CLIA certified commercially available platforms during routine clinical care. Detailed information of the assays can be found in supplementary table  1 . Data was collected from registered institutions between 4/1/2020 and 7/7/2021 using a standardized RedCap database. Only genomic alterations that were reported by the genomic testing platform was included for the analysis of this study. Raw genomic data was unavailable. This study was approved by local institutional review boards at participating sites per institutional policy and the Declaration of Helsinki. For the purpose of this study, we included castration resistant prostate cancer (CRPC) patients at the time of the first ARTA treatment and had available somatic genomic testing performed on blood or tissue (Fig. 1 ). Only samples that were collected after androgen deprivation therapy exposure were included in this study. Subjects not meeting these criteria or for whom these details could not be verified were excluded. Patients were then categorized as pre-ARTA or post-ARTA depending on whether the genomic sequencing sample was acquired before or after exposure to ARTA. Eligible patients received any ARTA, including abiraterone, apalutamide, darolutamide or enzalutamide. Gonadotropin-releasing hormone agonist/antagonist therapy and first-generation antiandrogens were not classified as ARTAs in this study. Fig. 1: Patient selection. aCastration status was determined at the first ARTA treatment initiation. bFor patients who had both germline and somatic testing, only somatic testing was used. cTime to progression, which was defined as initiation of first ARTA to treatment discontinuation. Abbreviations: AR androgen receptor, ARTA AR targeted agent, PSA prostate specific antigen, NGS next generation sequencing. Image was created with Cases were individually reviewed by a genomics expert in a multi-step quality control process. The RedCap database was queried for all patients marked as having an AR alteration. In a second step, to ensure all cases had been identified, the free text field containing the raw next generation sequencing (NGS) report (excluding protected health information) was separately queried to identify any unmarked AR alterations. At each institution at least 10% of the entries were quality controlled by a physician with a genomic expertize. Patients who had insufficient tumor for analysis or incomplete/missing NGS reports were excluded. Entries needing clarification were flagged and returned to the site for query resolution. After this two-stage process, a second genomics expert at the central site was consulted regarding any unclear entries. Outcome measures Data regarding patient demographic characteristics, PSA values, treatment types, genomic profile and assay type were extracted from the database. In patients with more than one genomic testing, only the first somatic genomic testing was included for the analysis. For patients in the pre-ARTA NGS group, the outcome measures of interest were PSA decline of ≥50%, time to progression (TTP), and overall survival (OS). Further, these outcome measures were compared based on AR alteration status (no alteration vs mutation or amplification). In the post-ARTA NGS group, the frequency of specific AR alterations (L702H, T878A, H875Y, W742C) was evaluated for their association with prior treatment exposures by the time of genomic testing and OS. TTP was defined as the time from the initiation of ARTA to treatment discontinuation due to clinical progression or censored at the time of the last documented follow-up. OS was calculated from the time of initiation of ARTA to death or censored at the time of the last follow-up. Statistical methods Descriptive statistics of patient characteristics and outcomes were described using proportions for categorical variables and median and interquartile range for continuous variables. Median TTP during the first ARTA treatment and median OS were estimated using the Kaplan-Meier method. The log-rank test was used to assess the differences in TTP and OS across subgroups, as defined by AR alteration status. Results Patient characteristics In total, 540 patients with CRPC who received an ARTA and had tissue (n = 321) and/or blood (n = 244) sample collection for genomic testing following androgen deprivation therapy exposure were identified using the PROMISE database. Median age was 62 (range: 39−90) years, and 55.2% had a Gleason score of ≥8 at the time of the diagnosis (Table  1 ). Among the entire population, the majority of patients were categorized as metastatic (92.5%; n = 500), and 7.4% (n = 40) had non-metastatic CRPC at the time of the first ARTA treatment. Table 1 Patient characteristics. Discussion Alterations in AR gene have long been noted as drivers in the progression of prostate cancer to its castration-resistant state. The increased availability of next generation sequencing and the advent of liquid biopsy has led to several publications outlining evolution of AR alterations during the course of prostate cancer treatment [ 21 , 22 ]. However, many studies have lacked granular clinical data in order to clearly define the association of AR alterations with specific treatment outcomes. Genomic reports often indicate whether benefit or lack of benefit is expected with various ARTA in the context of AR mutations or amplification, yet there are not enough data to clearly determine this, which is reflected in the conflicting recommendations seen in reports from different next generation sequencing providers. The PROMISE database, which included 1329 prostate cancer patients who had genomic testing data linked to detailed clinical treatment information, provides a unique opportunity to add new data to this area of uncertainty. Prior studies evaluating the impact of AR mutations on treatment outcomes have been small and/or included patients with prior ARTA exposure, since this is the group in which these mutations are most frequently seen. In our dataset we were able to identify 11 patients with AR mutations and 27 patients with AR amplifications that arose prior to any ARTA exposure. Our findings yielded the novel insight that AR amplifications are associated with longer time to clinical progression on first ARTA treatment compared to patients without an AR alteration. Whereas, in patients with AR mutation median TTP was similar to those without an AR alteration. Similar to ours, in one study which only a single genomic testing platform was used, median TTP in pre-ARTA mCRPC patients with ligand binding domain mutations was 6.2 months [ 23 ]. However, AR amplifications in this cohort was noted to be associated with poor prognosis. Further a shorter TTP trend in the group with higher copy number alterations was seen. Although it should be noted that our sample size is small, and these results might be driven by some outliers in our dataset. Several studies have demonstrated that patients with AR amplifications had worse clinical outcomes with ARTA treatment, however the majority of these studies included a mixed cohort of patients who were exposed to prior ARTA [ 15 , 16 , 24 , 25 , 26 ]. Further, in these studies, liquid biopsy was used to determine AR alterations. Since AR copy number gain is correlated with higher cell-free DNA levels which are often associated with higher tumor volume, liquid biopsy can create a confounding effect for the prognostic value of AR amplifications [ 27 ]. Similarly in our study, liquid biopsy was used in 40% of the patients and might be creating a similar confounding effect in this group. In another study, Jayaram and colleagues looked at a cohort from PCR2023 study ( identifier: NCT01867710) which included 133 baseline liquid biopsy samples of treatment naïve CRPC patients who were randomized to receive abiraterone acetate and one of four different glucocorticoid regimens [ 27 ]. Patients with AR copy number above ≥1.92 (n = 22) had shorter PFS and OS compared to those with AR copy number of <1.92. Although the increased copy number gain in this study was associated with worse clinical outcomes, authors did not use patients without an AR alteration as the comparator arm, making it hard to interpret the outcomes for these groups. AR mutations remain infrequent among treatment naïve prostate cancer patients but are detected in almost 20% of those with castration resistant disease, and in up to 40% of patients who have received ARTA [ 12 , 28 ]. There did not appear to be a unique genomic landscape among patients who develop AR alterations at castration resistance without prior ARTA compared to those who develop AR alterations after exposure to ARTA. It should be also noted that, in the current landscape where ARTA is being used in the metastatic hormone sensitive prostate cancer, we may see earlier emergence of these AR alterations and impact of these on other types of treatments used for mCRPC has not yet been explored. Similar to published literature, in our study cohort with castration resistant prostate cancer patients we found an increased rate of AR mutation frequency among those who received ARTA (19%) compared to those who did not (8%) as well as co-occurrence of AR amplification together with mutation which was not seen pre-ARTA exposure. In line with previous studies, the most common mutation in post-ARTA genomic reports in our study was L702H, which occurred with similar rates post abiraterone or enzalutamide [ 16 ]. In previous studies, this mutation was shown to be associated with resistance to abiraterone, and further androgen receptor signaling was shown to be activated by prednisone or progesterone in the presence of this mutation [ 17 , 29 , 30 ]. Although the numbers were small in our cohort, L702H was associated with higher 2-year OS compared to H875Y and W742C, which may imply better behavior or greater responsiveness to subsequent lines of therapy. Nevertheless, future drug development to target L702H will be critical since it is the most common, and the current AR degraders such as ARV-110 may be less effective in this subset [ 31 ]. Strengths of this analysis include having multiple commercial assays in a wide geographic range of prostate cancer patients being treated with standard therapies as opposed to restricting analysis to patients from one center and using one assay. This may increase the clinical applicability. Furthermore, genomic review by an expert ensured high quality data is the most critical aspect of this precision medicine effort. The current study represents real-world practice, and as such sample collection sites, genomic testing platforms and their associated methodologies were heterogenous. The sample size was limited by not all patients having a genomic testing following ARTA treatment. As a result, temporal and spatial heterogeneity, as well as differences in assay methodologies, lack of transcriptomic, and splice variant analysis may have limited the ability to identify all relevant alterations. In our study we used multiple commercial assays which is the regular clinical practice and these tests have different coverages and sequencing technologies causing variations in the results. These tests are also usually pan tumor and not prostate cancer specific and thus may not be designed to optimally detect all AR alterations or ETS rearrangements. Lastly, in real world setting, getting sequencing once either with liquid biopsy or archived tissue is common practice. This makes the results impactful and relevant to clinical practice even though the prior studies may have reported higher AR alteration prevalence [ 13 , 14 ]. Additionally, imaging practices were not uniform throughout this retrospective database, thus making the use of validated endpoints, including radiographic progression-free survival, impossible to ascertain. Despite this, we were able to examine overall survival among our study cohort along with clinically relevant endpoints such as PSA decline and time to treatment change, providing meaningful insight into disease progression. Future research efforts in this domain should include serial testing and enhanced inclusion of patients treated with specific therapies, as well as increasing the number of patients registered in databases such as PROMISE. Conclusions The current study utilized the PROMISE database to gain novel insight into the impact of AR amplifications and mutations on treatment response to ARTA. These findings highlight the need for prospective data or further rigorous database analyses to truly define whether treatment decision making should be impacted by detection of AR alteration on next-generation sequencing. Such steps will advance the potential for personalized medicine, and access to next generation sequencing platforms in advanced prostate cancer will remain central to its success. Data availability Competing interests ZBZ, NCH, AA, JJP, CN, ML, SR, GM and LG have no conflicts of interest that might be relevant to the contents of this manuscript. TD: Consulting: Bayer, Sanofi, Janssen, Astellas. CH: Stock holdings in Johnson and Johnson; research funding to institution from Merck, Bausch Health, Genentech, Bayer, and AstraZeneca, consultant fees from Tempus, Genzyme, and EMD Sorono, speaking fees from OncLive/MJH Life Sciences, travel fees from Merck. PB: Consultant (Institutional): Astellas; Eisai; Janssen, EMD Serono; Dendreon; Pfizer, Seattle Genetics, BMS, Bayer, Exelixis, AVEO Oncology, Guardant Health; Contracted Research (Institutional): AstraZeneca, Merck, AVEO Oncolgy; Research Grant (Institutional): BlueEarth Diagnostics, Exelixis; Speaker’s Bureau (Institutional): Bayer, Caris, Myovant. MAB: MAB has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed as outside of the current study. DK: D Kilari has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Eisai, Pfizer, Merck, Myovant and Sanofi and has received grants to his institution from Astellas, Genentech/Roche and Exelixis for work performed as outside of the current study. Speaker’s Bureau: Janssen. Seagen and Aveo oncology. AT: Honoraria from Urology times, Cardinal Health, Targeted Oncology; Consulting and advisory role at Foundation Medicine, Pfizer,Genzyme, EMD Serono, Exelixis, Seattle Genetics, Deka Biosciences; Instituional research funding from Clovis Oncology, Corvus Pharmaceuticals, Bayer, EMD Serono, Aravive, WindMIL Therapeutics, Bayer, Exact Sciences, Pfizer, Exelixis. RG: Institutional research funding by Endocyte/Advanced Accelerator Applications, Pfizer, Amgen, Immunomedics, Xencor. VSK: Dr. Koshkin has served in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seagen, Astellas, Dendreon, Guidepoint, GLG and ExpertConnect; has received research funding for the institution from Endocyte, Nektar, Clovis, Janssen, Seagen and Taiho and is supported by the Prostate Cancer Foundation. VGP: Vaibhav Patel is an employee of Arvinas. He has served as a consultant or advisor for Seagen and Sanofi Genzyme. MS: Paid consultant and/or received Honoria from Sanofi, AstraZeneca, PharmaIn and Resverlogix. He has received research funding to his institution from Zenith Epigenetics, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Madison Vaccines, Hoffman-La Roche, Tmunity, SignalOne Bio and Ambrx, Inc. AJA ScM: Paid consultant or advisor for Bayer, Myovant, Pfizer, Janssen, Bayer, Dendreon, Novartis, BMS, Merck, Astrazeneca, Forma, Astellas, Exelixis. Research support to Duke from Bayer, Pfizer, Janssen, Bayer, Dendreon, Novartis, BMS, Merck, Astrazeneca, Forma, Astellas, Amgen. RRM: Institutional research funding from Bayer, Tempus, AstraZeneca. Advisory Board/Consultant for Aveo, AstraZeneca, Bayer, Bristol Myers Squib, Calithera, Caris, Dendreon, Exelixis, Eli Lilly, Janssen, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento Therapeutics, Tempus, Telix. AA: Research funding through institution: MSD; AstraZeneca; Bristol-Myers Squibb; Astellas; Seattle Genetics; Genentech; Pfizer; Progenics; Prometheus; Eli Lilly; ASCO; Celgene; Harpoon Therapeutics. Compliance with ethical standards This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Additional information Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit .

Xencor Frequently Asked Questions (FAQ)

  • When was Xencor founded?

    Xencor was founded in 1997.

  • Where is Xencor's headquarters?

    Xencor's headquarters is located at 111 West Lemon Ave, Monrovia.

  • What is Xencor's latest funding round?

    Xencor's latest funding round is PIPE - II.

  • How much did Xencor raise?

    Xencor raised a total of $160.2M.

  • Who are the investors of Xencor?

    Investors of Xencor include Johnson & Johnson Innovation, Aimmune Therapeutics, Oxford Bioscience Partners, Zino Society, Zen Investments and 10 more.

  • Who are Xencor's competitors?

    Competitors of Xencor include PlantForm Corporation, Perseus Proteomics, Sutro Biopharma, Altor BioScience, Molecular Templates and 7 more.


Compare Xencor to Competitors

CoPlex Therapeutics

CoPlex Therapeutics is focused on R&D to provide neuroprotection from dementia caused by a protein complex that accumulates in the central nervous system and begins the cascade effect that leads to dementia including Alzheimer's.

Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

NellOne Therapeutics Logo
NellOne Therapeutics

NellOne Therapeutics is an early stage biopharmaceutical company with a focus on regenerative medicine. The company's main service is the development of treatments that utilize the NELL1 protein to promote tissue and bone regeneration, aiming to return damaged soft and hard tissue to its pre-injury state. NellOne primarily sells to the healthcare industry, with a particular focus on treatments for severe injuries and disorders in soft and hard tissues. It was founded in 2008 and is based in Knoxville, Tennessee.

Oxford BioTherapeutics Logo
Oxford BioTherapeutics

Oxford BioTherapeutics is a clinical stage oncology company that operates in the healthcare and biotechnology sectors. The company primarily focuses on the development of first-in-class immune therapies and antibody-drug conjugates, which are designed to improve outcomes for cancer patients, particularly those who respond poorly to PD-1 inhibitors. These therapies work by re-engaging the patient's immune system and directly targeting cancer cells. It is based in Oxfordshire, England.

Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

Alligator Bioscience

Alligator Bioscience is a company focused on the development of antibody-based drugs in the healthcare and biotechnology industry. The company's main offerings include the development of tumor-targeted immunotherapies, particularly agonistic mono- and bispecific antibodies, which are used in the treatment of cancer. It was founded in 2000 and is based in Lund, Sweden.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.